多黏菌素B治疗碳青霉烯类耐药肠杆菌科细菌感染的研究进展  

Research progress of polymyxin B in treatment of carbapenem-resistant enterobacteriaceae bacteria infections

作　　者：王雨豪(综述) 胡蓉 史家欣(审校) WANG Yuhao;HU Rong;SHI Jiaxin(Department of Pulmonary and Critical Care Medicine,Affiliated Lianyungang Hospital of Xuzhou Medical University,Lianyungang,Jiangsu 222000,China)

机构地区：[1]徐州医科大学附属连云港医院呼吸与危重症医学科,江苏连云港222000

出　　处：《重庆医学》2022年第15期2673-2677,2681,共6页Chongqing medicine

基　　金：国家自然科学基金项目(81300052);江苏省六大人才高峰项目(2019-SWYY-324);江苏省连云港市高新区科技局项目(ZD201932);江苏省连云港市卫生健康委员会科研项目(202016)。

摘　　要：碳青霉烯类耐药肠杆菌科细菌(CRE)在医疗机构的快速流行和传播,已成为全球公共卫生的重大问题。近年来,CRE的检出率在全球范围内呈逐年增高趋势,已被世界卫生组织(WHO)列为最重要的“紧迫”公共健康威胁之一;同时,CRE对常用抗菌药物耐药率逐渐增高,多重耐药及广泛耐药给临床治疗带来了巨大挑战。目前抗生素是治疗CRE感染的关键手段,但可用于经验性治疗的抗生素越来越少,因此,临床上对新型抗生素的需求十分迫切。已有多项研究显示,多黏菌素B具有抑制CRE的强大活性,本文将对多黏菌素B抗CRE的最新研究进展进行综述,以期为临床选择用药提供依据。The rapid epidemic and spread of carbapenem-resistant enterobacteriaceae(CRE)in medical institutions has been becoming a significant global public health issue.In recent years,the detection rate of CRE has showed the increasing trend year by year all over the world,and CRE has been listed as one of the most vital urgent public health threats by the WHO.At the same time,the resistance rate of CRE to commonly used antibiotics is gradually increasing,the multiple drug resistance and extensive drug resistance have brought great challenges to clinical treatment.Now antibiotics are the key measures to treat CRE infection,but there are fewer and fewer antibacterial drugs available for empirical treatment,so new type antibiotics are very urgent in clinic.A number of studies have shown that polymyxins B has powerful inhibitory activity against CRE.This article reviews the latest research progress of polymyxins B against CRE in order to provide a basis for clinical medication selection.

关 键 词：多黏菌素B 碳青霉烯类耐药肠杆菌科细菌 作用机制 不良反应 联合用药 

分 类 号：R978.1[医药卫生—药品]